|
|
|
|
|
|
|
|
|
|
Fulltext | Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, icatibant, imiquimod peritoneal lavage, and plerixafor | Journal of Cancer Therapeutics & Research
Conclusion
To improve the prognosis in EOC an effort to comprehensively block growth factors that have been identified as active in human EOC as suggested in this paper may prove fruitful. Past research indicates that several already-approved and marketed drugs might do this. The nine drugs have no clearly discernable interaction with each other and none would be expected to interfere with concomitant current cytotoxic chemotherapy regimens although such cannot be excluded. Given the safety of the nine drugs individually, and the poor prognosis of an EOC seeded peritoneum, the risk of unexpected side effects or interaction I believe is worth taking.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.